{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Class (Stereo):
CHEMICAL (ACHIRAL)
Guancydine, an antihypertensive agent which anti-angiotensin effect was not observed.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
FLUMIZOLE, a substituted diarylimidazole, is a weak acidic, nonsteroidal, anti-inflammatory agent. It is a potent cyclooxygenase inhibitor. FLUMIZOLE is severalfold more potent than indomethacin and 470 times more active than phenylbutazone in a system examining prostaglandin production.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Fluotracen (SKF-28,175) is a tricyclic drug which possesses dual antidepressant and antipsychotic activity mediated through blockage of GABA(A) receptors.
Status:
Investigational
Source:
NCT00699517: Phase 3 Interventional Completed Sarcoma
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Ombrabulin is an experimental drug candidate discovered by Ajinomoto and further developed by Sanofi-Aventis for cancer treatment.
Ombrabulin is a synthetic water-soluble analog of combretastatin A4, derived from the South African willow bush (Combretum caffrum), with potential vascular-disrupting and antineoplastic activities. Ombrabulin binds to the colchicine binding site of endothelial cell tubulin, inhibiting tubulin polymerization and inducing mitotic arrest and apoptosis in endothelial cells. As apoptotic endothelial cells detach from their substrate, tumor blood vessels collapse; the acute disruption of tumor blood flow may result in tumor necrosis. Ombrabulin has been used in trials studying the treatment of Sarcoma, Neoplasms, Solid Tumor, Neoplasms, Malignant, and Advanced Solid Tumors, among others. In January 2013, Sanofi said it discontinued development of Ombrabulin after disappointing results from phase III clinical trials.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Iliparcil was developed as an orally active beta-D-xyloside venous antithrombotic agent. However, the preclinical studies of this compound were discontinued.
Class (Stereo):
CHEMICAL (RACEMIC)
Solpecainol [EGIS 2936, EGYT 2936] is a sodium channel antagonist with antianginal and class I antiarrhythmic effects. It was in phase II clinical trials with Egis Pharmaceuticals for the treatment of angina pectoris and arrhythmias, but this development was discontinued.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Stenbolone is an anabolic–androgenic steroid of the dihydrotestosterone group patented by Schering AG but never marketed. Ester prodrug of stenbolone is used as an anabolic–androgenic steroid for depot intramuscular injection under the brand names Anatrofin and Stenobolone.
Status:
Investigational
Source:
NCT03184545: Phase 3 Interventional Recruiting Patellofemoral Pain Syndrome
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT04711915: Phase 1 Interventional Active, not recruiting Major Depressive Disorder
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Status:
Investigational
Source:
JAN:METOXADIAZONE [JAN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Metoxadiazone, a pesticide used as a household insecticide.